The U.S. Food and Drug Administration recently approved Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) for ...
If you have commercial insurance, you may be able to get FluMist delivered to your home. You may only need to pay an $8.99 ...
New LEQEMBI Companion™ program launched to expand helpful resources for patients throughout the treatment journey, including Nurse Educators who ...
The FDA has approved Merck & Co.’s under-the-skin version of Keytruda, reducing treatment time burden for patients while granting the world’s bestselling drug potential blockbuster revenue protection.
FDA approved pembrolizumab and berahyaluronidase alfa-pmph for patients aged 12 and older with solid tumors. Study MK-3475A-D77 showed a 45% ORR in subcutaneous administration for treatment-naïve ...
Pharmaceutical Technology on MSN
Halozyme eyes microparticles in $900m Elektrofi acquisition
Halozyme Therapeutics has agreed to acquire US-based Elektrofi in a deal worth up to $900m, adding microparticle capabilities to its portfolio of drug delivery technologies.
Pharmaceutical Technology on MSN
Novo Nordisk buys MASH specialist Akero for up to $5.2bn
Novo Nordisk has agreed to buy Akero Therapeutics in a deal rising to a potential $5.2bn, as the Danish drugmaker looks to ...
Patients can now receive treatment in as little as one to two minutes, compared to a 30-minute IV infusion New option offers greater convenience and flexibility in treatment settings, from hospitals ...
Saphnelo can now be administered subcutaneously rather than intravenously following the European regulator’s recommendation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback